PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for
their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making
cancer cells more sensitive to the drugs. Drugs used in chemotherapy, such as daunorubicin
and cytarabine, work in different ways to stop cancer cells from dividing so they stop
growing or die. Combining PKC412 with chemotherapy may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best way to give PKC412 when
given either after or together with daunorubicin and cytarabine in treating patients with
newly diagnosed acute myeloid leukemia.